SCH 51866

Drug Profile

SCH 51866

Latest Information Update: 18 Nov 1998

Price : $50

At a glance

  • Originator Schering-Plough
  • Class Antihypertensives; Antiplatelets; Vasodilators
  • Mechanism of Action Type 1 cyclic nucleotide phosphodiesterase inhibitors; Type 5 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Coronary artery restenosis; Hypertension; Thrombosis

Most Recent Events

  • 18 Nov 1998 No-Development-Reported for Coronary artery restenosis in USA (Unknown route)
  • 18 Nov 1998 No-Development-Reported for Hypertension in USA (Unknown route)
  • 18 Nov 1998 No-Development-Reported for Thrombosis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top